查詢結果分析
來源資料
相關文獻
- Clinical Evaluation of Primary Biliary Cirrhosis in Chinese Patients without Serum Anti-Mitochondrial Antibody
- Primary Biliary Cirrhosis in Antimitochondrial Antibody-Negative Patients: Chang Gung Memorial Hospital Experience
- Detection of Antibody to M2 Mitochondrial Antigen in Chinese Patients with Primary Biliary Cirrhosis
- 合併肝功能異常的多發性肌炎
- Prevalence of Autoantibodies in Uremic Patients with HCV Infection
- 抗核抗體與細胞生物學
- Association of HLA-Te22 Antigen with Anti-nuclear Antibodies in Chinese Patients with Erosive Oral Lichen Planus
- Ticlopidine-Induced Cholestatic Hepatitis with Anti-Nuclear Antibody in Serum
- Type 1 Autoimmune Hepatitis Mimic Cryptogenic Hepatitis
- 犬紅斑性狼瘡:臺灣首例病例報告
頁籤選單縮合
題 名 | Clinical Evaluation of Primary Biliary Cirrhosis in Chinese Patients without Serum Anti-Mitochondrial Antibody=中國人抗粒線體抗體陰性原發性膽汁性肝硬化之臨床評估 |
---|---|
作 者 | 李重賓; 黃信彰; 陳祖裕; 李發耀; 黃以信; 張扶陽; 李壽東; | 書刊名 | 中華醫學雜誌 |
卷 期 | 59:6 1997.06[民86.06] |
頁 次 | 頁334-340 |
分類號 | 415.534 |
關鍵詞 | 抗粒線體抗體; 抗核抗體; 自體免疫性膽管炎; 免疫球蛋白M; 原發性膽汁性肝硬化; Anti-mitochondrial antibody; Antinuclear antibody; Autoimmune cholangitis; Immunoglobulin M.; Primary biliary cirrhosis; |
語 文 | 英文(English) |
中文摘要 | 背景:原發性膽汁性肝硬化是一種慢性進行膽汁鬱滯性的肝臟疾病,其特性是經常可測到抗粒線體抗體(AMA)的存在,這種疾病在亞洲較為少見。抗粒線體抗體的存在與否是否會影響這個疾病的臨床、血清學和組織學表現,目前仍不清楚。 方法:我們研究在1972至1996這25年間,以臨床和╱或組織診斷的71位罹患原發性膽汁性肝硬化的中國人,其中的17位(24%)重複檢驗血清AMA皆呈陰性。我們比較血清AMA陽性和陰性之原發性膽汁性肝硬化患者的臨床、生化、免疫和組織的資料。 結果:與AMA陽性的患者比較,AMA陰性的患者有較低的平均血清免疫球蛋白M濃度(422 +/- 163比651 +/- 412 mg/dL, p = 0.042)。血清抗核抗體在AMA陰性的患者有93%為陽性,顯著地比AMA陽性患者的66%為高(p = 0.048)。兩組在年齡、性別、臨床症狀、肝生化指數、組織學的表現、存活率及對ursodeoxycholic acid的治療反應沒有顯著的差別。單變項邏輯迴歸分析顯示相對低血清免疫球蛋白M濃度、抗核抗體陽性及抗中心粒型抗核抗體為原發性膽汁性肝硬化患者AMA陰性的顯著預測因子(p值分別為0.035、0.044、0.029)。多變項分析顯示相對低血清免疫球蛋白M濃度為原發性膽汁性肝硬化患者AMA陰性的唯一獨立顯著預測因子(p = 0.015)。 結論:中國人原發性膽汁性肝硬化患者24%為血清AMA陰性,與AMA陽性患者相比較,顯示血清免疫球蛋白M濃度相對較低及血清抗核抗體陽性率較高是AMA陰性原發性膽汁肝硬化患者的特色。 |
英文摘要 | Background: Primary biliary cirrhosis (PBC), a chronic, progressive, cholestatic liver disease characterized by frequent presence of the anti-mitochondrial antibody (AMA), is rarely seen in the Asian population. Whether or not the presence of AMA alters the clinical, serological and histological features of the disease remains unclear. Methods: During the 25-year period from 1972 to 1996, 71 Chinese patients with PBC who were diagnosed clinically and/or histologically were reviewed. Seventeen (24%) of them repeatedly tested negative for serum AMA. Clinical, biochemical, immunological, histological data and treatment response to ursodeoxycholic acid were compared between PBC patients with positive and negative serum AMA. Results: Mean serum immunoglobulin M (IgM) level was significantly lower in AMA-negative PBC patients when compared with AMA-positive PBC patients (422 +/- 163 vs. 651 +/- 412 mg/dL, p=0.042). Serum anti-nuclear antibodies (ANA) were positive in 93% of the AMA-negative PBC patients, a significantly higher percentage when compared with the 66% of AMA-positive patients (p=0.048). There were no significant differences with regard to age, sex, clinical manifestations, liver biochemistries, histological findings, survival and response to l-year ursodeoxycholic acid treatment between the AMA-negative and AMA-positive patients. Univariate logistic regression analysis showed relatively lower serum IgM levels, positive serum ANA and anti-centromere type ANA were significant predictive factors to negative serum AMA in PBC patients (p=0.035, 0.044 and 0.029, respectively). Multi-variate analysis revealed relatively lower serum IgM levels were the only independent significant predictor to negative serum AMA in PBC patients (p=0.015). Conclusions: Twenty-four percent of Chinese patients with PBC were negative for serum AMA. AMA-negative PBC patients were characterized by relatively lower serum IgM levels and a higher rate of positive serum ANA. |
本系統中英文摘要資訊取自各篇刊載內容。